3月7日，业聚医疗（06929）发布截至2024年12月31日止年度的业绩公告。财务摘要显示如下图：

　　财务回顾中，经营利润为3221万美元。销售及分销开支上升至3740万美元，主要是由于2023年收购附属公司带来的额外经营开支。同时，研发开支增加至1700万美元，较去年增长18.5%。此外，其他收入净额显著下降79.8%至43万美元，主要因政府补助减少。

　　在管理层讨论与分析中，提到公司在亚太地区的收入增长显著，达5224万美元，同比增长43.7%。而来自美国市场的收入则下降17.7%至1750万美元，主要受到美元强势和市场整合的影响。整体来看，公司在多元化产品和市场扩展方面取得了一定进展，未来将继续关注研发和市场推广。

（文章来源：财中社）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.